Ensysce Publishes Phase 1 PF614-MPAR Data Demonstrating Oral Overdose Protection
Ensysce Biosciences published Phase 1 PF614-MPAR data in the Journal of Opioid Management, confirming its prodrug achieved normal opioid plasma levels while limiting delivery at supratherapeutic doses. MPAR technology has Breakthrough Therapy designation and IP protection extending through 2042, supporting its potential for safer analgesics.
1. Publication Milestone
Ensysce Biosciences achieved a milestone with the online publication of its first clinical paper on MPAR technology in the Journal of Opioid Management’s Jan/Feb 2026 issue, marking the first peer-reviewed report of an opioid overdose-limiting prodrug.
2. Phase 1 Study Findings
Phase 1 data demonstrate that PF614-MPAR maintained expected opioid plasma concentrations under prescribed dosing while preventing large increases in opioid delivery during supratherapeutic dosing, validating its overdose protection mechanism in humans.
3. Regulatory and IP Status
MPAR technology holds Breakthrough Therapy designation granted by the U.S. Food and Drug Administration in January 2024 and is protected by a robust intellectual property portfolio extending through 2042, reinforcing its commercial and developmental potential.
4. Pipeline Expansion
A second clinical trial evaluating MPAR is currently underway, and the platform is being expanded to develop safer formulations for amphetamines, methadone, ADHD treatments and opioid use disorder therapies.